ARIUS Receives Six Key US Patents
Strengthens Intellectual Property Portfolio on Lead Programs and Antibody Assets
The new patents cover the antibody molecules and various uses of each antibody and other similar antibodies to treat cancers such as ovarian, prostate and breast cancer. In addition, ARIUS has patent claims covering epitopes or specific parts of a cancer antigen target. According to ARIUS, this patent approach represents a large step up in value over more general target coverage because it is the epitope that determines what a cell will do when an antibody binds to it. In ARIUS' case, functional antibodies bind to epitopes that signal a cancer cell to die.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous